Targeted therapies are commonly designed to enhance recognition and clearance of disease-associated material. However, target engagement is not only determined by binding specificity or uptake efficiency; the receptor pathway through which cargo is acquired may also shape antigen-presenting cell function and downstream immune responses. Here, we investigated whether Gas6/TAM receptor-guided target-specific phagocytosis produces immune outcomes distinct from antibody-mediated recognition, using MOG-associated cargo as a model antigen system. Antibody-mediated recognition promoted uptake of live antigen-expressing target cells, whereas Gas6-based targeting showed limited uptake of live targets and preferentially promoted phagocytosis in an apoptotic antigen-expressing target context. In BMDC assays, Gas6-mediated myelin uptake was associated with increased PD-L1 expression but induced limited antigen-specific 2D2 T-cell proliferation under peptide-free conditions. In contrast, antibody-treated BMDCs induced detectable T-cell proliferation. These findings suggest that receptor-guided target-specific phagocytosis can influence antigen-presenting cell phenotype and downstream T-cell responses beyond cargo uptake alone.